Stock TOL TOLERANZIA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Toleranzia AB

Equities

TOL

SE0007438577

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
0.65 SEK +2.20% Intraday chart for Toleranzia AB -4.13% +51.87%
May. 31 Toleranzia AB Conducts Successful Safety Study of TOL2 in Blood Samples from Patients with Myasthenia gravis CI
May. 20 Toleranzia AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Announcement from the 2024 Annual General Meeting of Toleranzia AB (publ)
AQ
Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis
AQ
Toleranzia AB Conducts Successful Safety Study of TOL2 in Blood Samples from Patients with Myasthenia gravis
CI
Toleranzia : Annual General Meeting 2024 06 19 – Postal voting form
PU
Toleranzia : Annual General Meeting 2024 06 19 – Proxy form
PU
Toleranzia : Annual General Meeting 2024 06 19 – Annual Report 2023
PU
Toleranzia : Annual General Meeting 2024 06 19 – Auditor’s Report 2023
PU
Notice of Annual General Meeting in Toleranzia AB (publ)
AQ
Toleranzia AB: Interim report first quarter 2024
AQ
Toleranzia AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Toleranzia AB: Annual report for the financial year 2023
AQ
Toleranzia AB receives loan commitment of SEK 20 million
AQ
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program
AQ
Toleranzia AB – Year-End Report 2023
AQ
Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Toleranzia successfully completes GLP toxicology study of TOL2
AQ
Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2
CI
Toleranzia AB starts production of finished drug product for clinical studies
AQ
Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TOL Stock
  4. News Toleranzia AB